KYAN has over 100 drugs in inventory to be used for drug sensitivity testing with the Optim.AI™ platform without any lead time.
If your desired drug is not part of our inventory and it is a drug we can test in our assay, our team can source the drug within weeks.
| Nr. | Drug Name | Drug Classification | Biological Target |
|---|---|---|---|
| 1 | Abemaciclib | Kinase Inhibitor | CDK4, CDK6 |
| 2 | Acalabrutinib | Kinase Inhibitor | BTK (Bruton's Tyrosine Kinase) |
| 3 | Afatinib | Kinase Inhibitor | EGFR (ErbB1), HER2, ErbB4 |
| 4 | Alectinib | Kinase Inhibitor | ALK (Anaplastic Lymphoma Kinase) |
| 5 | Alpelisib | Kinase Inhibitor | PI3Kα (Phosphatidylinositol 3-kinase) |
| 6 | Anastrozole | Hormonal Therapy | Aromatase (CYP19A1) |
| 7 | Avapritinib | Kinase Inhibitor | KIT (Exon 17), PDGFRA (Exon 18) |
| 8 | Azacitidine | Antimetabolite (Epigenetic) | DNMT (DNA Methyltransferase) / RNA |
| 9 | Bendamustine | Alkylating Agent | DNA (Cross-linking) |
| 10 | Binimetinib | Kinase Inhibitor | MEK1, MEK2 |
| 11 | Bleomycin | Antitumor Antibiotic | DNA (Strand Scission) |
| 12 | Bortezomib | Proteasome Inhibitor | 26S Proteasome (Beta-5 subunit) |
| 13 | Cabozantinib | Kinase Inhibitor | VEGFR2, MET, RET, AXL |
| 14 | Capecitabine (5-FU) | Antimetabolite | Thymidylate Synthase (via 5-FU) |
| 15 | Capivasertib | Kinase Inhibitor | AKT (Protein Kinase B) |
| 16 | Carboplatin | Alkylating Agent | DNA (Cross-linking) |
| 17 | Carfilzomib | Proteasome Inhibitor | 20S Proteasome |
| 18 | Carmustine | Alkylating Agent | DNA (O6-guanine alkylation) |
| 19 | Ceritinib | Kinase Inhibitor | ALK |
| 20 | Cetuximab | Monoclonal Antibody | EGFR (ErbB1) |
| 21 | Chlorambucil | Alkylating Agent | DNA (Cross-linking) |
| 22 | Cisplatin | Alkylating Agent | DNA (Cross-linking) |
| 23 | Cladribine | Antimetabolite | DNA Polymerase / Ribonucleotide Reductase |
| 24 | Clofarabine | Antimetabolite | DNA Polymerase / Ribonucleotide Reductase |
| 25 | Cobimetinib | Kinase Inhibitor | MEK1 |
| 26 | Copanlisib | Kinase Inhibitor | PI3K (Alpha, Delta isoforms) |
| 27 | Crizotinib | Kinase Inhibitor | ALK, ROS1, MET |
| 28 | Cyclophosphamide | Alkylating Agent | DNA (Cross-linking) |
| 29 | Cyclosporine | Immunosuppressant | Calcineurin |
| 30 | Cytarabine | Antimetabolite | DNA Polymerase (via Ara-C) |
| 31 | Dabrafenib | Kinase Inhibitor | BRAF (V600E/K mutation) |
| 32 | Dacomitinib | Kinase Inhibitor | EGFR (ErbB1), HER2, ErbB4 |
| 33 | Daraxonrasib | RAS inhibitor | Active RAS proteins |
| 34 | Dasatinib | Kinase Inhibitor | BCR-ABL, SRC Family, c-KIT |
| 35 | Daunorubicin | Antitumor Antibiotic | DNA (Intercalation) / Topoisomerase II |
| 36 | Decitabine | Antimetabolite (Epigenetic) | DNMT (DNA Methyltransferase) |
| 37 | Defactinib | Investigational Inhibitor | FAK (Focal Adhesion Kinase) |
| 38 | Deferasirox | Iron Chelator | Iron (Fe3+) |
| 39 | Dexamethasone | Corticosteroid | Glucocorticoid Receptor |
| 40 | Docetaxel | Anti-Microtubule Agent | Microtubules (Stabilization) |
| 41 | Doxorubicin | Antitumor Antibiotic | DNA (Intercalation) / Topoisomerase II |
| 42 | Duvelisib | Kinase Inhibitor | PI3K (Delta, Gamma isoforms) |
| 43 | Enasidenib | Metabolic Inhibitor | IDH2 (Isocitrate Dehydrogenase 2) |
| 44 | Encorafenib | Kinase Inhibitor | BRAF (V600E) |
| 45 | Entrectinib | Kinase Inhibitor | NTRK, ROS1, ALK |
| 46 | Epirubicin | Antitumor Antibiotic | DNA (Intercalation) / Topoisomerase II |
| 47 | Eribulin | Anti-Microtubule Agent | Microtubules (Destabilization) |
| 48 | Erlotinib | Kinase Inhibitor | EGFR (Tyrosine Kinase) |
| 49 | Etoposide | Topoisomerase Inhibitor | Topoisomerase II |
| 50 | Everolimus | Kinase Inhibitor (mTOR) | mTORC1 |
| 51 | Fludarabine | Antimetabolite | DNA Polymerase / Ribonucleotide Reductase |
| 52 | Fruquintinib | Kinase Inhibitor | VEGFR 1, 2, 3 |
| 53 | Gefitinib | Kinase Inhibitor | EGFR (Tyrosine Kinase) |
| 54 | Gemcitabine | Antimetabolite | DNA Chain Elongation / Ribonucleotide Reductase |
| 55 | Gilteritinib | Kinase Inhibitor | FLT3, AXL |
| 56 | Idarubicin | Antitumor Antibiotic | DNA (Intercalation) / Topoisomerase II |
| 57 | Ifosfamide | Alkylating Agent | DNA (Cross-linking) |
| 58 | Imatinib | Kinase Inhibitor | BCR-ABL, KIT, PDGFR |
| 59 | Inobrodib | Investigational Epigenetic Modifier | p300 / CBP (Histone Acetyltransferases) |
| 60 | Irinotecan (SN-38) | Topoisomerase Inhibitor | Topoisomerase I |
| 61 | Ivosidenib | Metabolic Inhibitor | IDH1 (Isocitrate Dehydrogenase 1) |
| 62 | Ixazomib | Proteasome Inhibitor | 20S Proteasome (Beta-5 subunit) |
| 63 | L-Asparaginase | Enzyme | Asparagine (Amino Acid Depletion) |
| 64 | Lapatinib | Kinase Inhibitor | EGFR, HER2 |
| 65 | Lazertinib | Kinase Inhibitor | EGFR (Mutation specific) |
| 66 | Lenalidomide | Immunomodulator (IMiD) | Cereblon (E3 Ubiquitin Ligase) |
| 67 | Lenvatinib | Kinase Inhibitor | VEGFR, FGFR, PDGFR, RET, KIT |
| 68 | Letrozole | Hormonal Therapy | Aromatase (CYP19A1) |
| 69 | Melphalan | Alkylating Agent | DNA (Cross-linking) |
| 70 | Methotrexate | Antimetabolite | Dihydrofolate Reductase (DHFR) |
| 71 | Midostaurin | Kinase Inhibitor | FLT3, KIT |
| 72 | Mirvetuximab | Antibody-Drug Conjugate | Folate Receptor Alpha (FRα) |
| 73 | Mitomycin C | Antitumor Antibiotic | DNA (Cross-linking/Alkylation) |
| 74 | Mitoxantrone | Antitumor Antibiotic | Topoisomerase II / DNA Intercalation |
| 75 | Nilotinib | Kinase Inhibitor | BCR-ABL |
| 76 | Niraparib | PARP Inhibitor | PARP1, PARP2 |
| 77 | Olaparib | PARP Inhibitor | PARP1, PARP2, PARP3 |
| 78 | Oxaliplatin | Alkylating Agent | DNA (Cross-linking) |
| 79 | Paclitaxel | Anti-Microtubule Agent | Microtubules (Stabilization) |
| 80 | Palbociclib | Kinase Inhibitor | CDK4, CDK6 |
| 81 | Panobinostat | Epigenetic Modifier | Histone Deacetylases (Pan-HDAC) |
| 82 | Pazopanib | Kinase Inhibitor | VEGFR, PDGFR, KIT |
| 83 | Pemetrexed | Antimetabolite | DHFR, Thymidylate Synthase, GARFT |
| 84 | Pomalidomide | Immunomodulator (IMiD) | Cereblon (E3 Ubiquitin Ligase) |
| 85 | Ponatinib | Kinase Inhibitor | BCR-ABL (including T315I), VEGFR, FGFR |
| 86 | Procarbazine | Alkylating Agent | DNA / RNA / Protein Synthesis |
| 87 | Quizartinib | Kinase Inhibitor | FLT3 |
| 88 | Regorafenib | Kinase Inhibitor | VEGFR, TIE2, KIT, RET, RAF |
| 89 | Revumenib | Epigenetic Modifier | Menin (Menin-KMT2A Interaction) |
| 90 | Ripretinib | Kinase Inhibitor | KIT, PDGFRA (Switch Pocket) |
| 91 | Romidepsin | Epigenetic Modifier | Histone Deacetylases (HDAC1, HDAC2) |
| 92 | Ruxolitinib | Kinase Inhibitor | JAK1, JAK2 |
| 93 | Selinexor | Nuclear Export Inhibitor | XPO1 (Exportin 1) |
| 94 | Sorafenib | Kinase Inhibitor | VEGFR, PDGFR, RAF |
| 95 | Sotorasib | Kinase Inhibitor | KRAS G12C |
| 96 | Sunitinib | Kinase Inhibitor | VEGFR, PDGFR, KIT, FLT3 |
| 97 | Tamoxifen | Hormonal Therapy | Estrogen Receptor (ER) |
| 98 | Temozolomide | Alkylating Agent | DNA (O6-guanine methylation) |
| 99 | Thalidomide | Immunomodulator (IMiD) | Cereblon (E3 Ubiquitin Ligase) / VEGF |
| 100 | Tipiracil | Antimetabolite | Thymidine Phosphorylase (Protects Trifluridine) |
| 101 | Topotecan | Topoisomerase Inhibitor | Topoisomerase I |
| 102 | Trabectedin | Alkylating Agent | DNA Minor Groove |
| 103 | Trametinib | Kinase Inhibitor | MEK1, MEK2 |
| 104 | Trifluridine | Antimetabolite | DNA (Incorporation) |
| 105 | Valproic Acid | Epigenetic Modifier | Histone Deacetylase (HDAC) |
| 106 | Venetoclax | Apoptosis Inducer | BCL-2 |
| 107 | Vincristine | Anti-Microtubule Agent | Microtubules (Inhibition of Polymerization) |
| 108 | Vinorelbine | Anti-Microtubule Agent | Microtubules (Inhibition of Polymerization) |
| 109 | Zanubrutinib | Kinase Inhibitor | BTK (Bruton's Tyrosine Kinase) |